Literature DB >> 11112458

The prevention and treatment of vascular graft infection with a Triclosan (Irgasan)-bonded Dacron graft: an experimental study in the pig.

T Hernandez-Richter1, H M Schardey, F Löhlein, M M Heiss, M Redondo-Müller, C Hammer, F W Schildberg.   

Abstract

OBJECTIVES: to evaluate the role of Triclosan (Irgasan(R)) in the prevention of prosthetic graft infection.
MATERIAL AND METHODS: fifty-one pigs were assigned randomly to six groups. Group I (graft) and II (graft and Triclosan) were control groups. Groups III (graft) and IV (grafts and Triclosan) were contaminated with 2 x 10(7)CFU/ml S. aureus. Groups V (graft) and VI (graft and Triclosan) were intraoperatively contaminated with 2 x 10(7)CFU/ml S. aureus and reoperated on after 7 days. Remaining animals were sacrificed on day 28. The end point of the investigation was vascular graft infection, defined as the bacteriological and/or histological proof of infection. Results in both control groups no vascular graft infections were detected in Groups I and II. All of the group III animals presented but none of the group IV developed a graft infection (p <0.02). All of the group V animals presented and 10 of 12 animals developed a graft infection.
CONCLUSION: in this animal model Triclosan bonding appears effective in preventing prosthetic graft infection. However, the in situ replacement of Triclosan-protected grafts was not successful in the treatment of graft infection. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11112458     DOI: 10.1053/ejvs.2000.1199

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  5 in total

Review 1.  Bioprinting of freestanding vascular grafts and the regulatory considerations for additively manufactured vascular prostheses.

Authors:  Sara Abdollahi; Joseph Boktor; Narutoshi Hibino
Journal:  Transl Res       Date:  2019-06-03       Impact factor: 7.012

2.  Current options in prosthetic vascular graft infection: comparative analysis of 63 consecutive cases.

Authors:  Marcin Gabriel; Fryderyk Pukacki; Pawel Checinski; Grzegorz Oszkinis; Michal Stanisic; Maciej Zielinski; Katarzyna Pawlaczyk
Journal:  Langenbecks Arch Surg       Date:  2004-03-16       Impact factor: 3.445

Review 3.  Triclosan: a shot in the arm for antimalarial chemotherapy.

Authors:  Satish P Ramachandra Rao; Avadhesha Surolia; Namita Surolia
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

4.  An external ventricular drainage catheter impregnated with rifampicin, trimethoprim and triclosan, with extended activity against MDR Gram-negative bacteria: an in vitro and in vivo study.

Authors:  Roger Bayston; Waheed Ashraf; Ivan Pelegrin; Katherine Fowkes; Alison S Bienemann; William G B Singleton; Ian S Scott
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

Review 5.  ECM-based materials in cardiovascular applications: Inherent healing potential and augmentation of native regenerative processes.

Authors:  Anna V Piterina; Aidan J Cloonan; Claire L Meaney; Laura M Davis; Anthony Callanan; Michael T Walsh; Tim M McGloughlin
Journal:  Int J Mol Sci       Date:  2009-11-20       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.